Seeking Alpha

Roland Rick Perry's  Instablog

Roland Rick Perry
Send Message
Roland Rick Perry is the Managing Director of Institutional Analyst Inc. (IA), an independent investment research and investor relations firm, as well as editor of nine industry specific investment reviews. One of the best one mile runners to come out of the Chicago area, he attended Southern... More
My company:
My blog:
Internet Stock Review
View Roland Rick Perry's Instablogs on:
  • Over 50 Companies Invited To ICN Stem Cell Investor Conference.

    "Where Stem Cell Science, Meets Wall Street"

    NEW YORK, NY, Oct 12, 2015 (Marketwired via COMTEX) -- Investor Conference Network (-ICN-) announced today that over 50 private and publicly traded stem cell companies were invited to its upcoming conference in New York City, on October 26th and 27th at the 1st Annual Stem Cell Investor Conference.

    The invitation only conference, has invited over 58 of the leading stem cell companies including 39 from the U.S., seven from Australia, three from Israel and twelve others internationally, to present in front of hundreds of Wall Street institutional investors in the first "stem-cell-only" financial conference of its kind.

    "The larger the presenter attendance, the better the conference," stated Roland Rick Perry conference Chairman and managing director of Institutional Analyst Inc., which publishes the Stem Cell Stock Review. "We encourage institutional investors to call their portfolio companies listed below, to ensure their welcomed attendance and presentation."

    2015 Invited List:

    Actinogen Limited ($ACW.AX) - Australia Accurexa Inc. ($ACXA) AMAG Pharmaceuticals ($AMAG), Inc. Antisense Therapeutics Ltd. ($ANP.AX) Australia, Asterias Biotherapeutics, Inc. ($AST) Athersys, Inc. Brainstorm Cell Therapeutics Inc. ($BCLI), BioLife Solutions, Inc. ($BLFS), bluebird bio ($BLUE), Inc. Benitec Biopharma Limited ($BNTC), - Australia Bone Therapeutics SA, ($BOTHE.BR) - Belgium BioRestorative Therapies, Inc ($BRTX), BioTime, Inc. ($BTX), Capricor Therapeutics, Inc. ($CAPR) Cord Blood America Inc. $CBAI), Cellular Biomedicine Group Inc. ($CBMG) - China Cryo-Cell International, Inc. ($CCEL), Cellect Biomed Ltd. ($CLBD.TA),- Israel Caladrius Biosciences, Inc. ($CLBS)China Cord Blood Corporation ($CO) - China

    Cortendo/Stonebridge - Sweden, American Cryostem Corporation ($CRYO)

    Neuralstem, Inc. ($CUR), Cynata Therapeutics Limited ($CYP.AX0 - Australia, Cytori Therapeutics, Inc. ($CYTX), Fate Therapeutics, Inc. ($FATE), Fibrocell Science, Inc. ($FCSC)

    Harvard Apparatus Regenerative Technology, Inc. ($HART), Harvard Bioscience Inc. ($HBIO), Cellular Dynamics International, Inc. ($ICEL), ImmunoCellular Therapeutics, Ltd. ($IMUC), International Stem Cell Corporation ($ISCO), Kiadis Pharma ($KDS.AS) - Netherlands Kadimastem Ltd. ($KDST.TA)- Israel, Cesca Therapeutics Inc. ($KOOL). MiMedx Group, Inc. ($MDXG), Mesoblast Limited ($MEOBF) - Australia, Ocata Therapeutics, Inc. ($OCAT). Orthocell Limited ($OCC.AX) - Australia, Organovo Holdings, Inc. ($ONVO), Orgenesis Inc. ($ORGS)Osiris Therapeutics, Inc. ($OSIR), Aratana Therapeutics, Inc. ($PETK), ProtoKinetix Inc. ($PKTX), Pluristem Therapeutics, Inc. ($PSTI) - Israel

    ReNeuron Group plc ($RENE.L) - United Kingdom, RepliCel Life Sciences Inc. ($REPCF) - Canada, Regenicin, Inc. ($RGIN) Regenerx Biopharmaceuticals Inc. ($RGRX), Regeneus Ltd ($RGS.AX) - Australia,

    Reprocell ($4978) - Japan RTI Surgical Inc., ($RTIX) Strongbridge Biopharma PLC ($SBBP) - Sweden, IntelliCell BioSciences, Inc. ($SVFC),

    TiGenix N.V. ($TGXSF) - Belgium, Vericel Corporation ($VCEL), Vitro Diagnostics, Inc. ($VODG), Verastem, Inc. ($VSTM) Intrexon Corporation ($XON)

    The 2015 Stem Cell Conference will be held at two separate NYC locations and is by invitation only with presentations from 9am to 5pm. Titled "Where Stem Cell Science, Meets Wall Street" the conference will feature presentations by CEOs and CFOs and expert panels moderated by industry leaders.

    It is an opportunity for stem cell company management to meet the largest amount of Wall Street professionals' possible interested in stem cell science, ever assembled under one roof. This event is geared to investment bankers, buy- and sell-side investment analysts, fund managers and venture capital firms.

    For conference details and to see a list of invited presenters, visit

    To ensure optimal all-day institutional attendance, presentation schedules will only be released the day of the conference, at the conference entrance. A limited number of attendance tickets for $1,195 will be available on a first come first serve basis. Admission is complimentary for institutional investors and press.

    Video Interviews: Each presentation will be video taped and archived for later viewing at the Stem Cell Investor Conference website and at the Biotech Exec TV website, by FMW Media Works -- a leading financial broadcast provider. New To The Street will additionally be conducting "at conference" interviews with company executives to highlight late breaking news.

    Video scheduling is handled by Vincent Caruso at 631-465-0284

    Printed Interviews: Wall Street Analyzer (WSA) will also be available to conduct in-depth executive interviews. WSA's staff of writers and analysts goal, is to produce informative interviews that will help investors understand a companies' upside and provide company leadership vision.

    Scheduling is handled by Juan Costello at 347-529-5734

    Press Releases: Each presenter receives a complimentary conference participation press release from NewsMediaWire the leading search optimized press release distribution service for news, photos and multimedia content from public and private corporations, non-profit organizations, colleges and universities, government agencies and other public sector organizations.

    Contact Tom Speciale 310-492-4001 x 1

    Sponsorships: Sponsorship's include web and event and a full page in the Stem Cell Investor Conference Guide. There are also sponsorship opportunities for the lunch and cocktail party. Ideal for public company service providers. Please call Xavier Franco for details 310-924-4088

    About Stem Cell Investor Conference:

    The Stem Cell Investor Conference brings together both publicly traded and privately held stem cell companies and introduces their management directly to Wall Street. It is the only conference of its kind and designed to provide a forum where only Stem Cell related companies, network with select members of the institutional investment community.

    While there are many medical technology and biotech conferences held throughout year, the Stem Cell Investor Conference presents just stem cell companies. The conference is additionally inviting a broader base of professional investors from all segments of the micro-cap market (between $50 and $300 million) to participate, including aggressive hedge funds experienced at investing at the micro-cap level.

    About FMW MediaWorks/NTTS:

    Produced by FMW Mediaworks, "New To The Street" paves the way to the latest financial issues, offering a blend of business and financial services news reporting and in-depth interviews relating to new products, economic analysis and public company profiles. FMW Media Works Corp. a leading provider of business profiles and corporate special programming, and airs as paid-programming on select stations nationwide including The History Channel and A&E. reaching more than 95 million homes. Visit

    About NewMediaWire:

    By delivering news announcements and promotions in real time to thousands of national newspapers, broadcast outlets, search engines, news aggregators, individual journalists, blogs & websites, NewMediaWire helps drive traffic back to the issuers' newsroom or website to share the corporate story. News releases reach journalists, consumers, bloggers & key influencers via NewMediaWire's distribution channels, ultimately increasing the audience engagement. Visit:

    Contacts:Company and Institutional Invitations:Roland Rick PerryInstitutional Analyst Inc.roland@institutionalanalyst.com310-594-8062

    SOURCE: Investor Conference Network

    (NYSE:C) 2015 Marketwire L.P. All rights reserved.

    Oct 12 4:46 PM | Link | Comment!
  • Bio-AMD Advances Monitors For Both Wafarin/Coumadin Users And Heart Attack Victims.

    Tags: BIAD
    Jun 22 6:57 AM | Link | Comment!
  • Stem Cell Stock Review Updates Coverage On Accurexa (ACXA)

    BEVERLY HILLS, CA / ACCESSWIRE / June 12, 2015 / The Stem Cell Stock Review has updated coverage on the company and will be providing ongoing coverage. Roland Rick Perry, Editor of the Review stated "Accurexa's end goal is to provide a medical device that can save lives - not by improving the therapeutics or drugs used to treat neurological disorders including brain tumors, but rather by improving the delivery method and effectiveness of currently approved drugs - used to treat the disorders using a flexible delivery catheter." Adding, "The device called "Branchpoint" is designed to permit Clinicians to "tailor" therapeutic delivery and give physicians more precise control of the volume of therapeutics delivered and ensure that therapeutics delivered into the brain stay in the brain, avoiding the problem of reflux out to the brain surface. We are excited to update coverage as they progress towards their filing a 510k submission with the FDA."

    Accurexa's Branchpoint microinjection brain catheter can be described as a quantum leap and game changing advancement in the technology of delivering drugs and therapeutics, directly to the brain over the common syringe (or cannula), as depicted in the report. The device was recently subject of a cover story in Molecular Therapy(NYSE:R) (NYSE:MT) magazine, the official journal of the American Society for Gene & Cell Therapy. The report can be viewed at both the Stem Cell and Bioteck Stock Review websites.

    Stem Cell Stock Review Website:

    The Biotech Stock Review Website:

    About The Stem Cell Stock Review

    The Stem Stock Review website provides individual news feeds for each company on the Watch List, enabling investors to easily follow the entire group with a single visit. Each Friday we issue a weekly "head-line" wrap up of stem cell industry news via our free newsletter. Also included are links to third party industry expert websites and leading news sources such as the Life Sciences Report, Edison Research, Futurity, the Timmerman Report, Fierce Biotech, BioMed Reports, Science Daily and research reports from a broad spectrum of Wall Street sources.

    The Stem Cell Stock Review additionally has a Flipboard powered magazine which archives a collection of stem cell industry related articles from over 100 sources and can be found here: Stem Cell Stock Review Magazine:

    The Stem Cell Stock Review additionally has an online Internet TV channel called Biotech Exec TV, which hosts interviews with industry and Wall Street experts.

    Biotech Exec TV:

    About Institutional Analyst

    Institutional Analyst Inc. (IA), an independent investment research and investor relations firm. IA is a leading publisher of news, perspective and market intelligence reports on the equity markets. Working with publicly traded corporations, the firm seeks out small-cap companies which have products and/or services and management which can best be described as "best of breed." To best align itself with shareholders, IA typically seeks to have 90% of its retainer, represented by an equity stake in its client companies. When compensated for providing research reports or coverage, IA will provide all details on its website or report in a manner fully compliant with current regulatory guidelines. While we are not an impartial organization, we endeavor our best to initiate research coverage on companies which believe may perform well after initiating coverage. Founded in 1995 and based in Chicago, the heart of the trading industry, Institutional Analyst has offices in Beverly Hills, CA, Chicago IL, Delray Beach, FL and Port Jefferson, NY.


    Roland Rick Perry
    Managing Director, Institutional Analyst Inc.

    Legal Disclaimer

    Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.

    Institutional Analyst which owns The Stem Cell Stock Review is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release, For making specific investment decisions, readers should seek their own advice.

    Institutional Analyst which owns The Stem Cell Stock Review, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

    SOURCE: Institutional Analyst Inc.

    Jun 13 10:00 AM | Link | Comment!
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.